Viral and non-viral nanoplasmid vectors with improved production

Inventors

Williams, James A.

Assignees

Aldevron LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12600984-B2

Patent

Publication Date

2026-04-14

Expiration Date


Abstract

A method for improving the replication of a covalently closed circular plasmid is provided. The method includes providing a covalently closed circular plasmid having a Pol I-dependent origin of replication, and an insert including a structured DNA sequence selected from inverted repeat sequences, direct repeat sequences, homopolymeric repeat sequences, eukaryotic origins of replication or eukaryotic promoter enhancer sequences, wherein the structured DNA sequence is located at a distance of less than 1000 bp from the Pol I-dependent origin of replication in the direction of replication. The method also includes modifying the covalently closed circular recombinant molecule such that the Pol I-dependent origin of replication is replaced with a Pol III-dependent origin of replication, whereby the resultant Pol III-dependent origin of replication covalently closed circular plasmid has improved replication. An antibiotic marker free covalently closed circular recombinant DNA molecule is also provided.

Core Innovation

The disclosure describes a covalently closed circular plasmid with a backbone comprising a Pol III-dependent R6K origin of replication and an RNA-OUT RNA selectable marker. The backbone is less than 1000 bp, and the insert comprises a structured DNA sequence, including an inverted repeat, a direct repeat, or a eukaryotic origin of replication, located less than 1000 bp from the origin in the direction of replication. It also describes replicating this plasmid by subjecting a cell containing it to fermentation.

The supplied content reports that, compared with Pol I-dependent pUC vectors, R6K vectors replicate structured sequences with fewer replication intermediates and provide improved plasmid yield and quality. It also reports higher AAV plasmid yields and lentiviral titers, with reduced transfection-associated toxicity. The background section is not included in the supplied content, so the problem expressly identified there is not explicitly described in patent.

Claims Coverage

The two independent claims are claim 1, which covers a method for replicating a covalently closed circular plasmid, and claim 18, which covers the plasmid itself. They define two inventive features: the fermentation-based replication method and the plasmid composition.

Fermentation-based replication of a covalently closed circular plasmid

A method comprising a cell containing a covalently closed circular plasmid and subjecting the cell to a fermentation process. The plasmid has a backbone less than 1000 bp comprising a Pol III-dependent R6K origin of replication and an RNA-OUT RNA selectable marker, and an insert with an inverted repeat sequence, direct repeat sequence, or eukaryotic origin of replication located less than 1000 bp from the origin in the direction of replication.

Covalently closed circular plasmid with a short backbone and nearby structured DNA sequence

A covalently closed circular plasmid comprising a backbone less than 1000 bp with a Pol III-dependent R6K origin of replication and an RNA-OUT RNA selectable marker, and an insert comprising an inverted repeat sequence, direct repeat sequence, or eukaryotic origin of replication located less than 1000 bp from the origin in the direction of replication.

Claim 1 covers replication by fermentation of a cell containing the specified plasmid, while claim 18 covers the plasmid composition. Both independent claims specify the short backbone, the R6K origin and RNA-OUT marker, and the position and types of structured DNA sequence in the insert.

Stated Advantages

Compared with Pol I-dependent pUC vectors, R6K vectors are reported to replicate structured sequences with fewer replication intermediates.

R6K vectors are reported to provide improved plasmid yield and quality, including higher AAV plasmid yields and lentiviral titers.

The described system is reported to reduce transfection-associated toxicity.

Documented Applications

AAV plasmid production is described, with higher AAV plasmid yields reported for the R6K vectors.

Lentiviral vector production is described, with higher lentiviral titers reported.

Sleeping Beauty transposon vectors and polyA-repeat vectors are shown in the described vector maps.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.